Kisho

Charcot-Marie-Tooth diseaseTrials & approvalsNotable

The Charcot-Marie-Tooth disease clinical trial pipeline is gaining momentum with over 13 companies developing 15 pipeline drugs. One therapy currently in Phase II aims to enhance muscle function and reduce fatigue in patients.

DelveInsight s Charcot Marie Tooth Disease Pipeline Insight 2026 report provides comprehensive insights about 13 companies and 15 pipeline drugs in Charcot Marie Tooth Disease pipeline landscape It covers the Charcot Marie Tooth pipeline drug profiles including clinical and nonclinical ... Press release - DelveInsight Business Research LLP - Charcot Marie Tooth Disease Clinical Trial Pipeline Gains Momentum: 13+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - published on openPR.com By regulating this channel, it increases muscle excitability and enhances neuromuscular signal transmission. The therapy is being developed to improve muscle function and alleviate fatigue in patients with Charcot-Marie-Tooth disease. It is currently undergoing Phase II clinical evaluation for the treatment of Charcot-Marie-Tooth disease. @ https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Charcot Marie Tooth Pipeline Report • In September 2026 - Elpida Therapeutics updated its clinical study for ELP-02, a potential treatment for Charcot-Marie-Tooth Disease Type 4J (CMT4J). The first-in-human Phase 1/2 study is currently recruiting and is evaluating the safety, tolerability, and efficacy of a single intrathecal dose of ELP-02 in patients with CMT4J. • In July 2026, Novartis updated its first-in-human Phase 1 clinical trial of EDK060 for Charcot-Marie-Tooth Disease Type 1A (CMT1A). It covers the PI3K Inhibitor pipeline drug profiles, including PI3K Inhibitor clinical and nonclinical stage products. It also covers the PI3K Inhibitor therapeutics assessment by product type, stage, PI3K Inhibitor route of administration, and PI3K Inhibitor molecule type. It further highlights the inactive PI3K Inhibitor pipeline products in ... DelveInsight's "Glaucoma Treatment Market Insights, Epidemiology and Market Forecast 2034" report offers an in-depth understanding of Glaucoma, historical and forecasted epidemiology, as well as the market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Treatment & Clinical News6 days agoRead at source →

Original title: “Charcot Marie Tooth Disease Clinical Trial Pipeline Gains Momentum: 13+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight”

Kisho

Not rare diseases news,
news about your rare disease.

This week

The Charcot-Marie-Tooth disease clinical trial pipeline is gaining momentum with over 13 companies developing 15 pipeline drugs. One therapy currently in Phase II aims to enhance muscle function and reduce fatigue in patients.

Earlier

A study reports two cases of multiple sclerosis in a family affected by X-linked Charcot-Marie-Tooth disease, suggesting a potential link between these conditions. This research adds to the understanding of the genetic interplay in rare neurological disorders.

A recent study published in PubMed examines patient-reported complications and outcomes of various anesthesia types in individuals with Charcot-Marie-Tooth disease. This research provides valuable insights into the anesthesia management for this patient population.

A new publication outlines recommendations for the clinical development of therapies targeting Charcot-Marie-Tooth disease. The paper discusses optimal trial design, endpoints, and regulatory pathways to enhance the development process for this rare condition.

A recent study published in PubMed highlights novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease, based on insights from 10 families. This research contributes to the understanding of genetic diversity and clinical variability in this rare condition.

A case study highlights bilateral dumbbell-shaped ganglioneuroma of the C2 roots in a patient with Charcot-Marie-Tooth disease. This research contributes to the understanding of tumor presentations in rare neurological conditions.

Recent research highlights the role of peripheral myelin protein 22 in Charcot-Marie-Tooth disease, providing insights into its pathophysiology. Understanding this protein's function may lead to new therapeutic strategies for affected patients.

A qualitative study investigates the experiences of physical activity among individuals with Charcot-Marie-Tooth disease. The findings may provide insights into the challenges and benefits of exercise for this patient population.

Not rare diseases news,news about your rare disease.

This week

The Charcot-Marie-Tooth disease clinical trial pipeline is gaining momentum with over 13 companies developing 15 pipeline drugs. One therapy currently in Phase II aims to enhance muscle function and reduce fatigue in patients.

Earlier

A study reports two cases of multiple sclerosis in a family affected by X-linked Charcot-Marie-Tooth disease, suggesting a potential link between these conditions. This research adds to the understanding of the genetic interplay in rare neurological disorders.

A recent study published in PubMed examines patient-reported complications and outcomes of various anesthesia types in individuals with Charcot-Marie-Tooth disease. This research provides valuable insights into the anesthesia management for this patient population.

A new publication outlines recommendations for the clinical development of therapies targeting Charcot-Marie-Tooth disease. The paper discusses optimal trial design, endpoints, and regulatory pathways to enhance the development process for this rare condition.

A recent study published in PubMed highlights novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease, based on insights from 10 families. This research contributes to the understanding of genetic diversity and clinical variability in this rare condition.

A case study highlights bilateral dumbbell-shaped ganglioneuroma of the C2 roots in a patient with Charcot-Marie-Tooth disease. This research contributes to the understanding of tumor presentations in rare neurological conditions.

Recent research highlights the role of peripheral myelin protein 22 in Charcot-Marie-Tooth disease, providing insights into its pathophysiology. Understanding this protein's function may lead to new therapeutic strategies for affected patients.

A qualitative study investigates the experiences of physical activity among individuals with Charcot-Marie-Tooth disease. The findings may provide insights into the challenges and benefits of exercise for this patient population.

Not rare diseases news,
news about your rare disease.